BCMA rival to bluebird, Bristol Myers files for $100M IPO as the frontrunners stumble in a race to the finish line
On the same day that bluebird and Bristol Myers had to try and explain to analysts why their crucial application for the BCMA drug ide …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
